Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 8/20 | 0.76 |
| ▸ | TUBB | P07437 | 8/20 | 0.76 |
| ▸ | TUBA3C | P0DPH7 | 8/20 | 0.76 |
| ▸ | TUBA1B | P68363 | 8/20 | 0.76 |
| ▸ | TUBA4A | P68366 | 8/20 | 0.76 |
| ▸ | TUBB4B | P68371 | 8/20 | 0.76 |
| ▸ | TUBB3 | Q13509 | 8/20 | 0.76 |
| ▸ | TUBB2A | Q13885 | 8/20 | 0.76 |
| ▸ | TUBB8 | Q3ZCM7 | 8/20 | 0.76 |
| ▸ | TUBA3E | Q6PEY2 | 8/20 | 0.76 |
| ▸ | TUBA1A | Q71U36 | 8/20 | 0.76 |
| ▸ | TUBA1C | Q9BQE3 | 8/20 | 0.76 |
| ▸ | TUBB6 | Q9BUF5 | 8/20 | 0.76 |
| ▸ | TUBB2B | Q9BVA1 | 8/20 | 0.76 |
| ▸ | TUBB1 | Q9H4B7 | 8/20 | 0.76 |
| ▸ | GNG2 | P59768 | 1/20 | 0.74 |
| ▸ | GNB1 | P62873 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376314 | 1.00 | TUBB4A (0.76) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Colchinol SCHEMBL29915223 | 0.86 | TUBB1 (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL16120997 | 0.85 | GNG2 (0.83) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Deacetylcolchicine SCHEMBL13622201 | 0.85 | GNG2 (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Deacetylcolchicine SCHEMBL12091279 | 0.85 | GNG2 (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Deacetylcolchicine SCHEMBL29915209 | 0.85 | GNG2 (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Deacetylcolchicine SCHEMBL13259801 | 0.85 | GNG2 (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1822222 | 0.82 | KDM4E (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4374514 | 0.82 | GNG2 (0.71) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL13622222 | 0.82 | GNG2 (0.71) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622612-B2 | Tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2009-11-24 | — | — | US | disclosed |
| US-7622612-B2 | Tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2009-11-24 | — | — | US | disclosed |
| US-20070021427-A1 | Novel tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021427-A1 | Novel tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
| US-6846925-B2 | Colchinol derivatives as angiogenesis inhibitors | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2005-01-25 | — | — | US | disclosed |
| US-20040142909-A1 | Colchinol derivatives as angiogenesis inhibitors | ANGIOGENE PHARMACEUTICALS LIMITED | 2004-07-22 | — | — | US | disclosed |
| US-6720323-B2 | N-((5S)-3,9,10,11-TETRAMETHOXY-6,7-DIHYDRO-5H-DIBENZO(A,C) CYCLOHEPTEN-5-YL)-2-(2-AMINOACETYLAMINO)ACETAMIDE; DESTROYS NEWLY FORMED VASCULATURE WHILE LEAVING UNAFFECTED NORMAL, MATURE VASCULATURE. | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2004-04-13 | — | — | US | disclosed |
| US-20030195173-A1 | Colchinol derivatives as angiogenesis inhibitors | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| EP-1301498-A1 | COLCHINOL DERIVATIVES AS ANGIOGENESIS INHIBITORS | Angiogene Pharmaceuticals Limited (GB) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002008213-A1 | COLCHINOL DERIVATIVES AS ANGIOGENESIS INHIBITORS | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195173-A1 | Colchinol derivatives as angiogenesis inhibitors | FLT1, CCNO, FLT4 | TUBB4A 734/4885TUBB 327/4885TUBA3C 228/4885 |
| US-20070021427-A1 | Novel tricyclic derivatives and their use | NFATC1, IL2, CCL2 | TUBB4A 45/4885TUBB 35/4885TUBA3C 63/4885 |
| US-20040142909-A1 | Colchinol derivatives as angiogenesis inhibitors | FLT1, CCNO, FLT4 | TUBB4A 748/4885TUBB 334/4885TUBA3C 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.